Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Making LDL Matter Again: Addressing Clinical, Patient, and Payer Barriers in ASCVD Management : Episode 10
Nonstatin Therapy Decisions
Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.
EP: 1.Understanding the Current State of LDL-C Goal Attainment and Barriers to Adequate Control in Hyperlipidemia
EP: 2.Challenges with Undertreatment in Hyperlipidemia and Opportunities to Address this Gap
EP: 3.Pharmacy-Driven Challenges
EP: 4.Real-World Insights and PROMPT-LIPID
EP: 5.Social Determinants of Health
EP: 6.The 2013 Guideline Shift
EP: 7.Unintended Consequences of Metric Changes
EP: 8.Reinstating LDL-C Targets
EP: 9.International LDL Thresholds
Now Viewing
EP: 10.Nonstatin Therapy Decisions
Panelists discuss how clinicians decide when to introduce nonstatin low-density lipoprotein (LDL)–lowering agents such as ezetimibe or PCSK9 inhibitors. The choice depends on residual LDL levels, patient risk category, and prior therapy response.
They emphasize early combination therapy for high-risk patients, noting that waiting for repeated therapy failures delays optimal outcomes.
Panelists stress that structured treatment algorithms and patient follow-up can ensure timely intensification and reduce long-term cardiovascular risk.
Related Videos
Related Content
